Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Candesartan Reduces Chronic Heart Failure: ESC Meeting
September 8, 2003
- BI to Further Collaborate with Japanese Firms: Prof. Krebs
September 1, 2003
- REGULATORY NEWS IN BRIEF
September 1, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 1, 2003
- ON THE MOVE
September 1, 2003
- Dainippon to Promote Better Cancer Pain Management
September 1, 2003
- Don Quijote to Provide Free OTC Drugs in Late Night Emergencies
September 1, 2003
- Merck & Co. Determined to Acquire All Shares of Banyu
September 1, 2003
- Anti-fatigue Food, Drug Development Project to Start from October: Soiken
September 1, 2003
- Antitumor Drug TZT-1027 Could Be Major Global Product: Teikoku Hormone
September 1, 2003
- G&G Enters Capital, Business Tie-up with Toyo Pharmar
September 1, 2003
- Kaken Considers Global Development with Fiblast
September 1, 2003
- Shipment of PPA-containing OTC Drugs Stopped
September 1, 2003
- Neoral Patent Litigation Between Novartis and Merck Hoei Continues
September 1, 2003
- BULLETIN
September 1, 2003
- Kyowa, Kyorin to Copromote Allelock to Facilities with Less than 100 Beds
September 1, 2003
- OTC NEWS IN BRIEF
September 1, 2003
- BUSINESS NEWS IN BRIEF
September 1, 2003
- DIAGNOSTIC NEWS IN BRIEF
September 1, 2003
- WEBSITE NEWS
September 1, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…